188 related articles for article (PubMed ID: 32047167)
21. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells.
Pappano WN; Zhang Q; Tucker LA; Tse C; Wang J
BMC Cancer; 2014 Jun; 14():430. PubMed ID: 24927813
[TBL] [Abstract][Full Text] [Related]
22. FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition.
Diab A; Gem H; Swanger J; Kim HY; Smith K; Zou G; Raju S; Kao M; Fitzgibbon M; Loeb KR; Rodriguez CP; Méndez E; Galloway DA; Sidorova JM; Clurman BE
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28287-28296. PubMed ID: 33093209
[TBL] [Abstract][Full Text] [Related]
23. Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy.
Esposito F; Giuffrida R; Raciti G; Puglisi C; Forte S
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639030
[TBL] [Abstract][Full Text] [Related]
24. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
[TBL] [Abstract][Full Text] [Related]
25. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.
Garimella SV; Rocca A; Lipkowitz S
Mol Cancer Res; 2012 Jan; 10(1):75-85. PubMed ID: 22112940
[TBL] [Abstract][Full Text] [Related]
26. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
[TBL] [Abstract][Full Text] [Related]
27. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
[TBL] [Abstract][Full Text] [Related]
28. Targeted inhibition of the WEE1 kinase as a novel therapeutic strategy in neuroendocrine neoplasms.
Weindl L; Atreya I; Dietrich P; Neubeck S; Neurath MF; Pavel M
Endocr Relat Cancer; 2021 Jul; 28(9):605-620. PubMed ID: 34128828
[TBL] [Abstract][Full Text] [Related]
29. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
[TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
[TBL] [Abstract][Full Text] [Related]
31. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
Elbæk CR; Petrosius V; Sørensen CS
Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the
Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398
[TBL] [Abstract][Full Text] [Related]
33. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
[TBL] [Abstract][Full Text] [Related]
34. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p.
Li D; Tang X; Li M; Zheng Y
J Cell Biochem; 2019 Aug; 120(8):12290-12299. PubMed ID: 30805988
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
Mak JP; Man WY; Ma HT; Poon RY
Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.
Ha DH; Min A; Kim S; Jang H; Kim SH; Kim HJ; Ryu HS; Ku JL; Lee KH; Im SA
Sci Rep; 2020 Jun; 10(1):9930. PubMed ID: 32555285
[TBL] [Abstract][Full Text] [Related]
38. Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells.
Nojima H; Homma H; Onozato Y; Kaida A; Harada H; Miura M
Exp Cell Res; 2020 Jan; 386(2):111720. PubMed ID: 31738907
[TBL] [Abstract][Full Text] [Related]
39. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.
Harris PS; Venkataraman S; Alimova I; Birks DK; Balakrishnan I; Cristiano B; Donson AM; Dubuc AM; Taylor MD; Foreman NK; Reigan P; Vibhakar R
Mol Cancer; 2014 Mar; 13():72. PubMed ID: 24661910
[TBL] [Abstract][Full Text] [Related]
40. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
